Catalog No.
DHC04202
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
Plasma thromboplastin antecedent, PTA, Coagulation factor XI, F11, FXI
Concentration
1.47 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03951
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
NVS250519, CAS: 2098724-83-3,FXI, FXIa,
Clone ID
Abelacimab
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71., PMID:40499984
DOAC-Stop™ reverses the anticoagulant effect of asundexian and milvexian., PMID:40484204
Anticoagulation in Atrial Fibrillation: Is a Paradigm Shift From Xa to XIa Inhibitors on the Horizon?, PMID:40439401
Factor XI/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation with stroke risk: a GRADE-assessed meta-analysis of randomized controlled trials., PMID:40377680
Targeting factor XI as a compromise between thrombosis and bleeding., PMID:40357657
Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start?, PMID:40248290
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Reply., PMID:40239083
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation., PMID:40239082
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation., PMID:40239081
A Systematic Review of Factor XI/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation., PMID:40232269
AZALEA-TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain., PMID:40063336
The emerging role of anticoagulants targeting Factor XI in thromboembolism management., PMID:39943830
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation., PMID:39842011
New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis., PMID:39675564
The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo., PMID:39549166
Factor XI inhibitors - Rising stars in anti-thrombotic therapy?, PMID:39094433
Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review., PMID:39077577
Therapeutic Potential of FXI Inhibitors: Hype or Hope?, PMID:39073551
Factor XI inhibition in cardiovascular disease., PMID:38984712
Factor XI inhibition in patients with acute coronary syndrome., PMID:38867863
Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition., PMID:38545505
Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance., PMID:38534886
Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors., PMID:37606428
Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?, PMID:37580207
Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors., PMID:37422330
News at XI: moving beyond factor Xa inhibitors., PMID:37116752
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis., PMID:36841245
Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions., PMID:36398362
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism., PMID:36386334
Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin., PMID:34871049
Abelacimab for Prevention of Venous Thromboembolism. Reply., PMID:34731547
Abelacimab for Prevention of Venous Thromboembolism., PMID:34731546
Abelacimab for Prevention of Venous Thromboembolism., PMID:34731545
Abelacimab for Prevention of Venous Thromboembolism., PMID:34731544
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa., PMID:34714969
Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism., PMID:34519340
Abelacimab for Prevention of Venous Thromboembolism., PMID:34297496
For research use only. Not for human or drug use.
